Stay updated with breaking news from Takeaim Leukemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eric Winer, MD, discusses the safety and efficacy outcomes of the TakeAim Leukemia trial and future research with emavusertib in combination therapies.
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.
Alice Mims, MD, discusses the toxicity profile and initial efficacy of emavusertib in heavily pretreated, FLT3-mutated relapsed/refractory AML.
Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance...
Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib